Winterstein Research Group

Refining drug benefit. Reducing risk. Improving outcomes.

Drugs are approved based on favorable risk-benefit among the few select patients who enrolled in clinical trials. What happens after a drug comes to the market and is used by more diverse patient populations is sometimes a different story. We work to optimize drug outcomes by evaluating millions of real-world patients to learn who benefits from a particular drug and who does not, and how we can use drugs effectively after weighing risk and benefit – considering children and adults.